Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in East Asian Participants With Overweight or Obesity
Latest Information Update: 12 Jul 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms OASIS 2
- Sponsors Novo Nordisk
- 05 Sep 2023 Status changed from active, no longer recruiting to completed.
- 31 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Nov 2021 New trial record